BIONET Therapeutics Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-97.43	-86.26	-37.34	-12.52
Depreciation & Amortization	11.77	3.24	0.58	-
Loss (Gain) From Sale of Investments	-0.14	-0.71	-0.03	-
Stock-Based Compensation	18.69	3.71	0.16	-
Provision & Write-off of Bad Debts	0.01	0.01	-	-
Other Operating Activities	-1.64	-4.99	-1.6	-
Change in Accounts Receivable	-13.24	-10.27	-1.17	-
Change in Inventory	-0.56	-29.15	-0.37	-
Change in Accounts Payable	-8.88	11.61	4.55	1.17
Change in Unearned Revenue	6.98	1.71	2.61	-
Change in Other Net Operating Assets	13.55	2.69	-1.55	7.87
Operating Cash Flow	-57.48	-108.4	-34.16	-3.47
Capital Expenditures	-81.19	-46.56	-12.1	-
Sale (Purchase) of Intangibles	-2	-0.46	-	-
Investment in Securities	219	-723.08	-478.99	-
Other Investing Activities	-0.06	-0.68	-0.01	-
Investing Cash Flow	135.75	-770.79	-491.09	-
Long-Term Debt Repaid	-0.71	-	-	-
Net Debt Issued (Repaid)	-0.71	-	-	-
Issuance of Common Stock	-	855.85	516.57	96
Financing Cash Flow	-0.71	855.85	516.57	96
Net Cash Flow	77.56	-23.33	-8.67	92.53
Free Cash Flow	-138.68	-154.96	-46.26	-3.47
Free Cash Flow Margin	-89.77%	-190.56%	-861.52%	-
Free Cash Flow Per Share	-1.98	-2.70	-3.06	-3.17
Cash Income Tax Paid	-	0.71	0.02	-
Levered Free Cash Flow	-158.65	-116.82	-33.11	-
Unlevered Free Cash Flow	-158.6	-116.82	-33.11	-
Change in Working Capital	11.26	-23.4	4.07	9.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.